Literature DB >> 11724831

Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.

R Tedeschi1, M Enbom, E Bidoli, A Linde, P De Paoli, J Dillner.   

Abstract

Viral load is an important marker of activity of viral diseases for a number of viruses. We wished to evaluate whether the viral load of human herpesvirus 8 (HHV-8) in peripheral blood was a consistent feature of Kaposi's sarcoma (KS) patients and whether the viral load correlated with human immunodeficiency virus (HIV) RNA levels, CD4 counts, and/or the HHV-8 seroreactivity. Fifty-four consecutive plasma samples from 14 patients with KS were evaluated for HHV-8 viral load by quantitative real-time PCR. Samples were analyzed at the start of highly active antiretroviral therapy (HAART) and at different intervals during treatments. The median HHV-8 DNA load before HAART treatment was 8,998 (ranging from 170 to 40,100) copies/ml and 12,270 (ranging from 40 to 142,575) copies/ml during HAART. There were both increasing and decreasing trends. There was an association between HHV-8 DNA and HIV RNA viral loads (odds ratio [OR] = 5.40; 95% confidence interval [95% CI], 1.54 to 18.98) and between HHV-8 viral load and CD4 cell counts (OR = 7.24; 95% CI, 1.30 to 40.35). High HHV-8 viral load was also correlated with the titers of antibodies to the lytic HHV-8 antigen detected with immunofluorescence (P < 0.01), but not with antibodies to the latent HHV-8 antigen. In conclusion, we found that HHV-8 viremia in KS is associated with HIV viral load, CD4 cell counts, and lytic HHV-8 serological reactivity. HHV-8 viral load monitored by real time PCR might be useful for determination HHV-8 viral load during the follow-up of KS patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724831      PMCID: PMC88535          DOI: 10.1128/JCM.39.12.4269-4273.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  44 in total

1.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

2.  Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor.

Authors:  D A Rizzieri; J Liu; S T Traweek; G D Miralles
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

3.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.

Authors:  O Pleskoff; C Tréboute; A Brelot; N Heveker; M Seman; M Alizon
Journal:  Science       Date:  1997-06-20       Impact factor: 47.728

4.  Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy.

Authors:  J M Orenstein; S Alkan; A Blauvelt; K T Jeang; M D Weinstein; D Ganem; B Herndier
Journal:  AIDS       Date:  1997-04       Impact factor: 4.177

5.  Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents.

Authors:  L M Barkholt; H Dahl; M Enbom; A Lindé
Journal:  Transpl Int       Date:  1996       Impact factor: 3.782

6.  Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients.

Authors:  E T Lennette; D J Blackbourn; J A Levy
Journal:  Lancet       Date:  1996-09-28       Impact factor: 79.321

7.  Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.

Authors:  P S Moore; L A Kingsley; S D Holmberg; T Spira; P Gupta; D R Hoover; J P Parry; L J Conley; H W Jaffe; Y Chang
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

8.  Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction.

Authors:  P Secchiero; D R Carrigan; Y Asano; L Benedetti; R W Crowley; A L Komaroff; R C Gallo; P Lusso
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

9.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

10.  The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients.

Authors:  L L Decker; P Shankar; G Khan; R B Freeman; B J Dezube; J Lieberman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  Multiplex detection of human herpesviruses from archival specimens by using matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Malin I L Sjöholm; Joakim Dillner; Joyce Carlson
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

3.  Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda.

Authors:  Angela Nalwoga; Marjorie Nakibuule; Vickie Marshall; Wendell Miley; Nazzarena Labo; Stephen Cose; Denise Whitby; Robert Newton
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

4.  Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance.

Authors:  Francesco Broccolo; Simona Bossolasco; Anna M Careddu; Giuseppe Tambussi; Adriano Lazzarin; Paola Cinque
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

5.  Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.

Authors:  Emanuele Amodio; James J Goedert; Patrizia Barozzi; Giovanni Riva; Alberto Firenze; Filippa Bonura; Enza Viviano; Nino Romano; Mario Luppi
Journal:  Cancer Sci       Date:  2011-07-28       Impact factor: 6.716

6.  Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids.

Authors:  Francesco Broccolo; Giuseppe Locatelli; Loredana Sarmati; Sara Piergiovanni; Fabrizio Veglia; Massimo Andreoni; Stefano Buttò; Barbara Ensoli; Paolo Lusso; Mauro S Malnati
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

7.  Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection.

Authors:  Elisa Martró; Michael J Cannon; Sheila C Dollard; Thomas J Spira; A Scott Laney; Chin-Yih Ou; Philip E Pellett
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions.

Authors:  Martin M Nsubuga; Robert J Biggar; Susan Combs; Vickie Marshall; Georgina Mbisa; Fred Kambugu; Meghna Mehta; Benon Biryahwaho; Charles S Rabkin; Denise Whitby; Sam M Mbulaiteye
Journal:  Cancer Lett       Date:  2008-01-30       Impact factor: 8.679

9.  Association of NFκB and related-cytokines with the viral load and development of antibodies against HHV-8 in people living with HIV/AIDS.

Authors:  Juliana Prado Gonçales; Thaísa Regina Rocha Lopes; Virginia Maria Barros de Lorena; Melayne Rocha Aciole; José Valter Joaquim Silva Júnior; Tania Regina Tozetto-Mendoza; Paulo Henrique Braz-Silva; Maria Rosangela Cunha Duarte Coêlho
Journal:  Med Microbiol Immunol       Date:  2019-10-04       Impact factor: 3.402

10.  Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays.

Authors:  Francesco Broccolo; Paolo Scarpellini; Giuseppe Locatelli; Anna Zingale; Anna M Brambilla; Paola Cichero; Leonardo A Sechi; Adriano Lazzarin; Paolo Lusso; Mauro S Malnati
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.